Bellerophon Therapeutics
formerly BellerophonIPOPublic · Warren, United States
- Headquarters
- Warren, New Jersey
- Employees
- 11–50
- Business Model
- B2B
- Website
- bellerophon.com
- Type
- Public
About
Bellerophon Therapeutics is a clinical-stage biopharmaceutical company developing INOpulse, a pulsed, inhaled nitric oxide delivery system for pulmonary arterial hypertension and related cardiopulmonary conditions. The company (NASDAQ/OTC: BLPH) has run multiple Phase 2b/3 clinical trials evaluating INOpulse across different patient populations, including pulmonary hypertension associated with fibrotic interstitial lung disease.
Summary
Bellerophon Therapeutics is a Biotech company based in Warren, United States. Investors include Cowen and Company and SVB Leerink.
Exit History
Feb 2015
Investors
Similar Companies

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...

Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bellerophon-therapeutics"><img src="https://indexed.vc/api/badge/company/bellerophon-therapeutics" alt="Bellerophon Therapeutics on Indexed.vc" width="260" height="76" /></a>
